Nafarelin(acetate) , ≥98% , 86220-42-0
Synonym(s):
5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-3-(2-naphthyl)-D-alanyl-L-leucyl-L-arginyl-L-prolylglycinamide acetate salt hydrate
CAS NO.：86220-42-0
Empirical Formula: C68H89N17O16
Molecular Weight: 1400.54
MDL number: MFCD00895733
| Pack Size | Price | Stock | Quantity |
| 500ug | RMB588.00 | In Stock |
|
| 1mg | RMB1124.00 | In Stock |
|
| 5mg | RMB3976.00 | In Stock |
|
| 10mg | RMB6880.00 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | >181oC (dec.) |
| storage temp. | 2-8°C |
| solubility | H2O: >5mg/mL |
| form | solid |
| color | white |
| EPA Substance Registry System | Nafarelin acetate (86220-42-0) |
Description and Uses
Nafarelin acetate is a synthetic decapeptide agonist analog of the natural gonadotropin-releasing hormone, differing in the amino acid at position 6 where D-naphthylalanine has been substituted for glycine. This substitution gives nafarelin greater potency and a substantially longer half-life than the endogenous hormone. Nafarelin acetate administered as a nasal spray, suppresses estrogen levels on repeated dosing and is indicated for the management of endometriosis. It also has orphan drug status for use in precocious puberty.
Nafarelin Acetate is a gonadotropin-releasing hormone agonist. Treatment with Nafarelin improves sleep disturbances and anxiety-depression. Nafarelin is also used in the treatment of estrogen-dependent gynecologic disorders such as endometriosis and uterine leiomyomas.
Safety
| WGK Germany | 3 |
